TW200612902A - Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester - Google Patents

Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester

Info

Publication number
TW200612902A
TW200612902A TW094114589A TW94114589A TW200612902A TW 200612902 A TW200612902 A TW 200612902A TW 094114589 A TW094114589 A TW 094114589A TW 94114589 A TW94114589 A TW 94114589A TW 200612902 A TW200612902 A TW 200612902A
Authority
TW
Taiwan
Prior art keywords
cholesterol
lipase
agents
absorption
suppressing
Prior art date
Application number
TW094114589A
Other languages
Chinese (zh)
Inventor
Toshio Hayami
Hideyuki Kishida
Naoki Arai
Shinnichi Yokota
Kazuya Hamada
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of TW200612902A publication Critical patent/TW200612902A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)

Abstract

The present invention has found that human and porcine pancreatic lipase and cholesterol esterase inhibitory activities and the like are possessed by a licorice or licorice extract which has been previously taken orally, or are sufficient in meal experience in the form of a medicine, a chinese herbal remedy, a food additive such as sweetener, or a health food product, or by glabridin, glabrol, glabrene, and 4'-O-methylglabridin contained therein. In addition, it has been proved that giving a feed containing any of these materials to experimental animals suppressed their obesity, and produced the increased excretion of neutral fats and cholesterol into feces, thereby suppressing their absorption in the body. This has enabled the supply of compositions for reducing neutral fats or cholesterol absorption, or for suppressing obesity based on lipase and/or cholesterol inhibition, totally different from dietary fiber-containing compositions which have previously been used commonly.
TW094114589A 2004-05-13 2005-05-05 Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester TW200612902A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004143210 2004-05-13
JP2004271567 2004-09-17

Publications (1)

Publication Number Publication Date
TW200612902A true TW200612902A (en) 2006-05-01

Family

ID=35393981

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094114589A TW200612902A (en) 2004-05-13 2005-05-05 Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester

Country Status (3)

Country Link
JP (1) JPWO2005110400A1 (en)
TW (1) TW200612902A (en)
WO (1) WO2005110400A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689081A (en) * 2016-08-31 2019-04-26 釜山大学校产学协力团 Localised adiposities therapeutic composition and micropin comprising it
CN115925778A (en) * 2022-12-13 2023-04-07 五邑大学 A kind of glycyrrhetinic acid-dodecane-cholesterol compound and its synthesis method and application
CN116322651A (en) * 2020-10-07 2023-06-23 株式会社钟化 Transthyretin tetramer stabilizer, and transthyretin amyloidosis preventive or progression inhibitor

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808333A (en) 2006-04-17 2008-02-16 Kaneka Corp Licorice polyphenol preparation
JPWO2008143182A1 (en) * 2007-05-17 2010-08-05 株式会社カネカ Composition containing licorice polyphenol
WO2009025277A1 (en) 2007-08-22 2009-02-26 Kaneka Corporation Method of producing reduced coenzyme q10 and method of stabilizing the same
EP2234493A4 (en) * 2007-12-21 2011-05-25 Univ Cincinnati THERAPEUTIC USE OF CARBOXYLTER LIPASE INHIBITORS
JP2011231057A (en) * 2010-04-28 2011-11-17 Kao Corp Ceramide production enhancer
JP6236697B2 (en) * 2012-12-27 2017-11-29 株式会社ゆふ・は Absorbing material and soap using the same
JP7535838B2 (en) * 2017-08-10 2024-08-19 小林製薬株式会社 Lipid excretion promoter
JP7602854B2 (en) * 2017-08-10 2024-12-19 小林製薬株式会社 Bofutsushosan Extract
JP2021187801A (en) * 2020-06-03 2021-12-13 小林製薬株式会社 Lipid excretion promoter
CN113598253A (en) * 2021-07-14 2021-11-05 云南润攀生物科技有限公司 Ketogenic herbal tea for promoting ketogenic effect and increasing body fat decomposition
CN115736054B (en) * 2022-12-05 2024-09-03 安徽农业大学 Blood glucose-reducing lipid-lowering solid wolfberry flower tea and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000226324A (en) * 1998-11-30 2000-08-15 Kansai Koso Kk Liquid agent composition for cleaning/wiping and for cosmetic water
IL138603A0 (en) * 2000-09-21 2001-10-31 Ready Made 37 1999 Ltd Licorice extract for use as a medicament
TWI329516B (en) * 2000-12-12 2010-09-01 Kaneka Corp Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
CN1599602A (en) * 2001-10-11 2005-03-23 钟渊化学工业株式会社 Peroxisome proliferator activated receptor ligands and process for producing the same
JP4191420B2 (en) * 2002-03-26 2008-12-03 株式会社カネカ Edible oil and fat composition comprising a licorice hydrophobic extract

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689081A (en) * 2016-08-31 2019-04-26 釜山大学校产学协力团 Localised adiposities therapeutic composition and micropin comprising it
CN109689081B (en) * 2016-08-31 2022-12-16 Sn维亚股份有限公司 Composition for partial obesity treatment and microneedle containing same
CN116322651A (en) * 2020-10-07 2023-06-23 株式会社钟化 Transthyretin tetramer stabilizer, and transthyretin amyloidosis preventive or progression inhibitor
CN115925778A (en) * 2022-12-13 2023-04-07 五邑大学 A kind of glycyrrhetinic acid-dodecane-cholesterol compound and its synthesis method and application

Also Published As

Publication number Publication date
JPWO2005110400A1 (en) 2008-03-21
WO2005110400A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
TW200612902A (en) Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester
MX2009007014A (en) Ground meat and meat analog compositions having improved nutritional properties.
ATE495674T1 (en) FRUIT CHOCOLATE OR SIMILAR
PT1455600E (en) Food or pet food composition containing plant extract from amelanchier for bone health
WO2009010368A3 (en) Composition comprising bacteria and lecithin
WO2009047754A3 (en) Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
WO2006108582A3 (en) Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
MY160409A (en) Compositions for preventing or improving gastrointestinal diseases
MY145662A (en) Nutrition for obese patients
EP1781107A4 (en) Herbal pharmaceutical compositions for prophylaxis and/or treatment of cardiovascular diseases and the method of preparing the same
GB0615781D0 (en) Prebiotic composition
WO2008102017A3 (en) Food comprising polyunsaturated fatty acids for the prevention of chronic diseases
MX2007004879A (en) Protection of bioactive food ingredients by means of encapsulation.
DE602004016120D1 (en) USE OF BANANA EXTRACT FOR THE TREATMENT OF INFLAMMATORY DISEASE
WO2005051290A3 (en) Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone
MX2010009315A (en) Nutritional compositions for promotion of bone growth and maintenance of bone health comprising extracts of for example rosemary or caraway.
WO2006109194A3 (en) Chromium-fatty acid compounds and methods of making and using thereof
CR8265A (en) MILK FRACTIONS AND MILK PREPARATIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES MEDIATED BY COX-2
WO2011019210A3 (en) Dietary supplement, feed and pharmaceutical composition containing chia seed and maca, and preparation method thereof
MX356253B (en) Coating.
EP1548445A3 (en) Novel targets for obesity from fat tissue
BRPI0519901A2 (en) plant extracts and methods and uses
EP1819724A4 (en) Compositions containing beta 2-glycoprotein i for the prevention and/or treatment of vascular disease
GB0422929D0 (en) Bioactive vitamin D analogues
MY139463A (en) Food or pet food composition containing plant extract from amelanchier for bone health